Imperial College London
Portrait Picture

ProfessorNicholaCooper

Faculty of Medicine, Department of Immunology and Inflammation

Professor of Immune Haematology
 
 
 
//

Contact

 

n.cooper

 
 
//

Assistant

 

Miss Mandy Sale +44 (0)20 3313 4017

 
//

Location

 

4S10CCommonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Neunert:2019:10.1182/bloodadvances.2019000966,
author = {Neunert, C and Terrell, DR and Arnold, DM and Buchanan, G and Cines, DB and Cooper, N and Cuker, A and Despotovic, JM and George, JN and Grace, RF and Kühne, T and Kuter, DJ and Lim, W and McCrae, KR and Pruitt, B and Shimanek, H and Vesely, SK},
doi = {10.1182/bloodadvances.2019000966},
journal = {Blood Advances},
pages = {3829--3866},
title = {American Society of Hematology 2019 guidelines for immune thrombocytopenia},
url = {http://dx.doi.org/10.1182/bloodadvances.2019000966},
volume = {3},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - <jats:title>Abstract</jats:title><jats:sec><jats:title>Background:</jats:title><jats:p>Despite an increase in the number of therapies available to treat patients with immune thrombocytopenia (ITP), there are minimal data from randomized trials to assist physicians with the management of patients.</jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p>These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about the management of ITP.</jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p>In 2015, ASH formed a multidisciplinary guideline panel that included 8 adult clinical experts, 5 pediatric clinical experts, 2 methodologists with expertise in ITP, and 2 patient representatives. The panel was balanced to minimize potential bias from conflicts of interest. The panel reviewed the ASH 2011 guideline recommendations and prioritized questions. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including evidence-to-decision frameworks, to appraise evidence (up to May 2017) and formulate recommendations.</jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p>The panel agreed on 21 recommendations covering management of ITP in adults and children with newly diagnosed, persistent, and chronic disease refractory to first-line therapy who have non–life-threatening bleeding. Management approaches included: observation, corticosteroids, IV immunoglobulin, anti-D immunoglobulin, rituximab, splenectomy, and thrombopoietin receptor agonists.</jats:p></jats:sec><jats:sec><jats:title>Conclusions:</jats:title><jats:p>There was a lack of evidence to support strong recommendations for
AU  - Neunert,C
AU  - Terrell,DR
AU  - Arnold,DM
AU  - Buchanan,G
AU  - Cines,DB
AU  - Cooper,N
AU  - Cuker,A
AU  - Despotovic,JM
AU  - George,JN
AU  - Grace,RF
AU  - Kühne,T
AU  - Kuter,DJ
AU  - Lim,W
AU  - McCrae,KR
AU  - Pruitt,B
AU  - Shimanek,H
AU  - Vesely,SK
DO  - 10.1182/bloodadvances.2019000966
EP  - 3866
PY  - 2019///
SN  - 2473-9529
SP  - 3829
TI  - American Society of Hematology 2019 guidelines for immune thrombocytopenia
T2  - Blood Advances
UR  - http://dx.doi.org/10.1182/bloodadvances.2019000966
VL  - 3
ER  -
Download